| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-726 | |
| Phytochemical name or plant extracts | 23-epi-26-deoxyactein | |
| PMID | 30584366 | |
| Literature evidence | CONCLUSION: These results suggested that the selective compounds isolated from C. yunnanensis Hsiao could be the promising new agents for TNBC treatment. | |
| IUPAC name | [(1R,1'R,3'R,4R,4'R,5R,5'R,6'R,10'S,12'S,13'S,16'R,18'S,21'R)-1,4',6',12',17',17'-hexamethyl-18'-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosane]-3'-yl] acetate | |
| Phytochemicals’ class or type of plant extracts | Triterpenoid | |
| Source of phytochemicals or plant Extracts | Cimicifuga yunnanensis | |
| Geographical availability | China North-Central, China South-Central | |
| Plant parts | Rhizome | |
| Other cancers | Breast cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 3.1 µg/mL against MCF-7 2.5 µg/mL against MDA-MB-231 5.5 µg/mL against SKBR-3 | |
| Potency | Notably, we found that compounds 4 and 13 have promising antitumor effect on MDA-MB-231, a highly aggressive TNBC cell line. | |
| Cell line/ mice model | MCF-7, MDA-MB 231, SK-BR3 | |
| Additional information | These results suggested that the selective compounds isolated from C. yunnanensis Hsiao could be the promising new agents for TNBC treatment. | |
| PubChem ID | 21668683 | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:709452-1 | |
| Safety | NA |